Summit Therapeutics (SMMT) Total Current Liabilities (2016 - 2025)
Historic Total Current Liabilities for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to $64.9 million.
- Summit Therapeutics' Total Current Liabilities rose 1003.07% to $64.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.9 million, marking a year-over-year increase of 1003.07%. This contributed to the annual value of $41.7 million for FY2024, which is 10450.38% up from last year.
- As of Q3 2025, Summit Therapeutics' Total Current Liabilities stood at $64.9 million, which was up 1003.07% from $60.3 million recorded in Q2 2025.
- In the past 5 years, Summit Therapeutics' Total Current Liabilities registered a high of $140.2 million during Q2 2024, and its lowest value of $11.9 million during Q2 2023.
- In the last 5 years, Summit Therapeutics' Total Current Liabilities had a median value of $25.6 million in 2021 and averaged $43.4 million.
- As far as peak fluctuations go, Summit Therapeutics' Total Current Liabilities tumbled by 6889.34% in 2022, and later surged by 107482.19% in 2024.
- Summit Therapeutics' Total Current Liabilities (Quarter) stood at $25.6 million in 2021, then skyrocketed by 51.36% to $38.8 million in 2022, then crashed by 47.39% to $20.4 million in 2023, then soared by 104.5% to $41.7 million in 2024, then soared by 55.59% to $64.9 million in 2025.
- Its Total Current Liabilities stands at $64.9 million for Q3 2025, versus $60.3 million for Q2 2025 and $34.9 million for Q1 2025.